RB transcriptional corepressor like 1Genealiases: CP107 · PRB1 · p107
Q-omics provides the consensus-scored RBL1 profile across patient tissues and cancer cell-line models. RBL1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RBL1 is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, RBL1 RNA expression shows 21,689 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, BLCA, and GBM as cancer lineages where RBL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBL1 survival associations across molecular data types. RBL1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBL1 RNA expression–survival associations across cancer types. High RBL1 expression shows unfavorable associations in MESO, KIRP, KICH, ACC and LIHC, but favorable associations in UCS. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for RBL1 RNA expression.
This table summarizes RBL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for RBL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBL1 shows higher tumor expression in BLCA, HNSC, KIRC, COAD, KIRP and LIHC. The BLCA box plot shows higher RBL1 RNA expression in tumor versus normal tissue (log2 FC = +1.387, t-test p < 0.001).
This table shows molecular features associated with RBL1 in patient tissues and cancer cell lines. In patient samples, RBL1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RBL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
